Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve in the small group of patients receiving exogenous surfactant therapy in this small, single center study, the primary goal is to first determine feasibility and safety.
Description: Count of any decreases in oxygenation, expressed as PaO2 (mmHg) / FiO2 (% oxygen as a decimal), of greater than 20% during the BLES treatment and up to 30 minutes post-treatment. Change will be calculated relative to pre-treatment values.
Measure: Adverse events (patient) - Decrease in oxygenation Time: 3 days post-randomizationDescription: Count of any decrease in mean arterial blood pressure >10 mmHg or requirement for >20% increase in vasopressor dose during the BLES procedure and up to 30 minutes post-treatment. Change will be calculated relative to the pre-treatment values.
Measure: Adverse events (patient) - Decrease in hemodynamics Time: 3 days post-randomizationDescription: Number of circuit breaches. Count of any circuit breach immediately prior to and during each BLES treatment procedure will be recorded.
Measure: Adverse event (healthcare worker) - Circuit breach Time: 3 days post-randomizationDescription: Count of healthcare personnel involved in the BLES procedure developing symptoms and testing positive for COVID-19.
Measure: Adverse event (healthcare worker) - COVID-19 symptoms Time: 2 weeks post-randomizationDescription: PaO2 (in mmHg) / FiO2 (percentage oxygen expressed as a decimal) ratios captured from clinical chart
Measure: Change in oxygenation Time: Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.Description: Lung compliance captured from the ventilators, expressed in mL/cm H2O.
Measure: Change in Lung compliance Time: Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.Description: The number of days the patient is receiving mechanical ventilation.
Measure: Ventilated days Time: From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 daysDescription: The number of days the patient is admitted to the ICU
Measure: Length of ICU stay Time: From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 daysDescription: The number of days the patient is admitted to the hospital
Measure: Length of hospital stay Time: From hospital admission until hospital discharge or death, whichever comes first, assessed up to 60 daysDescription: Number of patients who die within 30 days of ICU admission
Measure: Mortality Time: 30 daysDescription: G-CSF, in pg/mL, from multiplex cytokine arrays
Measure: G-CSF levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: GM-CSF, in pg/mL, from multiplex cytokine arrays
Measure: GM-CSF levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: IFN gamma, in pg/mL, from multiplex cytokine arrays
Measure: IFN gamma levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: IL-1 beta, in pg/mL, from multiplex cytokine arrays
Measure: IL-1 beta levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: IL-4, in pg/mL, from multiplex cytokine arrays
Measure: IL-4 levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: IL-6, in pg/mL, from multiplex cytokine arrays
Measure: IL-6 levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: IL-10, in pg/mL, from multiplex cytokine arrays
Measure: IL-10 levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: I, in pg/mL, from multiplex cytokine arrays
Measure: I levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: MCP-1, in pg/mL, from multiplex cytokine arrays
Measure: MCP-1 levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Description: TNF alpha, in pg/mL, from multiplex cytokine arrays
Measure: TNF alpha levels (serum inflammatory biomarker) Time: ICU day 0, 1, 3 and 7 (7 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports